Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia.
To investigate the cause and effect relationship between hyperinsulinemia and the increased amounts of farnesylated p21Ras, we performed hyperinsulinemic euglycemic clamps in normal weight volunteers as well as in normal mice and dogs. Insulin infusions significantly raised the amounts of farnesylated p21Ras in the white blood cells of humans, in liver samples of mice and dogs, and in aorta samples of mice. Obese hyperinsulinemic individuals and dogs (made hyperinsulinemic by surgical diversion of the pancreatic outflow from the portal vein into the vena cava) displayed increased amounts of farnesylated p21Ras before the hyperinsulinemic clamps. Infusions of insulin did not alter the already increased levels of farnesylated p21Ras in these experimental models. To further investigate the role of acquired insulin resistance in modulating insulin's effect on p21Ras prenylation, we induced insulin resistance in rats by glucosamine infusion. Insulin-resistant glucosamine-treated animals displayed significantly increased farnesylated p21Ras in response to insulin infusion compared to that in control saline-treated animals. Transgenic models of insulin resistance (heterozygous insulin receptor substrate-1 knockout mice, A-ZIP/F-1 fatless mice, and animals overexpressing glutamine:fructose-6-phosphate amidotransferase) contained increased amounts of farnesylated p21Ras. We conclude that hyperinsulinemia, either endogenous (a prominent feature of insulin resistance) or produced by infusions of insulin, increases the amounts of farnesylated p21Ras in humans, mice, and dogs. This aspect of insulin action may represent one facet of the molecular mechanism of the potentially detrimental influence of hyperinsulinemia.
Draznin
B
B
Denver Veterans Affairs Medical Center, Department of Medicine, University of Colorado Health Sciences Center, 80220, USA. drazninb@den-res.org
Miles
P
P
Kruszynska
Y
Y
Olefsky
J
J
Friedman
J
J
Golovchenko
I
I
Stjernholm
R
R
Wall
K
K
Reitman
M
M
Accili
D
D
Cooksey
R
R
McClain
D
D
Goalstone
M
M
D000328:Adult; D000818:Animals; D004285:Dogs; D005260:Female; D005944:Glucosamine / Q000494:pharmacology; D006801:Humans; D006946:Hyperinsulinism / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D007328:Insulin / Q000494:pharmacology / Q000502:physiology*; D055504:Insulin Receptor Substrate Proteins; D007333:Insulin Resistance / Q000235:genetics / Q000502:physiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout / Q000235:genetics; D008817:Mice, Mutant Strains; D008875:Middle Aged; D010750:Phosphoproteins / Q000235:genetics; D017368:Protein Prenylation / Q000187:drug effects; D016283:Proto-Oncogene Proteins p21(ras) / Q000378:metabolism*; D051381:Rats; D020742:rhoA GTP-Binding Protein / Q000378:metabolism
C526292:IRS1 protein, human; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; C526295:Irs1 protein, mouse; C526296:Irs1 protein, rat; D010750:Phosphoproteins; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras); D020742:rhoA GTP-Binding Protein; D005944:Glucosamine